Vogler, Meike <br/><br/>
Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo.  [electronic resource] 

 -  Cancer research  Oct 2008 
 - 7956-65 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1538-7445 
<br/><br/><label>Standard No.: </label>10.1158/0008-5472.CAN-08-1296  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--drug therapy<br/>Animals<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Cell Proliferation--drug effects<br/>Chick Embryo<br/>Drug Resistance, Neoplasm--drug effects<br/>Drug Synergism<br/>Female<br/>Genes, bcl-2--physiology<br/>Humans<br/>Mice<br/>Mice, Nude<br/>Pancreatic Neoplasms--drug therapy<br/>RNA, Small Interfering--administration & dosage<br/>TNF-Related Apoptosis-Inducing Ligand--administration & dosage<br/>Tumor Cells, Cultured<br/>X-Linked Inhibitor of Apoptosis Protein--antagonists & inhibitors<br/>Xenograft Model Antitumor Assays